New bedside test could help doctors fine-tune antibiotics in real time
NCT ID NCT07666230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test a new, fast method to measure levels of beta-lactam antibiotics in the blood of intensive care patients. Researchers will compare the new method with standard lab tests using daily blood samples from 200 patients. The goal is to develop a point-of-care tool that allows doctors to quickly adjust antibiotic doses for better treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- beta-lactam antibiotics
- What this could lead to
- If successful, this could enable doctors to quickly adjust antibiotic doses for ICU patients, improving treatment effectiveness.
- What could go wrong
- This is an early-stage method validation study, not a treatment trial. The new test may not be accurate enough or practical for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patents that are treated with beta-lactam antibiotics in the ICU or IMC unit of the Department of General Surgery at UMG
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Valid informed consent form (prospective, retrospective, or provided by a legal representative) * Antibiotic therapy with a beta-lactam antibiotic in the intensive care unit or intermediate care unit of the Department of General Surgery at UMG Exclusion Criteria: * Patients without a valid informed consent form
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bacterial infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two blood tests may separate real kidney harm from a false alarm
- Can a computer model speed up sepsis blood tests?
- Could a simple blood test curb antibiotic overuse in sick kids?
- New drug CTX-187 takes aim at stubborn bacterial infections
- Can smarter antibiotic choices curb superbugs in liver disease?
- Vaccine Follow-Up: how long does protection last in babies?